Seth Lerner, MD
About
Research
Publications
2025
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Scott Lucia M, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. Npj Digital Medicine 2025, 8: 174. PMID: 40121304, PMCID: PMC11929913, DOI: 10.1038/s41746-025-01560-y.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerResponse to neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerPredicting response to neoadjuvant chemotherapyOptimal treatment strategyImprove patient survivalImproving clinical outcomesGene expression profilesBladder preservationPredictive biomarkersPatient survivalUnnecessary treatmentClinical outcomesTreatment responseRNA sequencingTumor heterogeneityTreatment strategiesClinical trialsGene signatureExpression profilesMolecular determinantsCancerChemotherapyBuilding accurate predictive modelsIMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-cause mortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodIMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerBladder sparing therapyAll-cause mortalityOncological outcomesRadical cystectomyCancer-specific mortalityNon-invasive diseaseBCG-unresponsiveBladder cancerPathological outcomesT1 diseaseT1 patientsCIS patientsMedian timeProgression to muscle-invasive bladder cancerBCG-unresponsive NMIBC patientsImpact of pathological stageImpact of tumor stageInternational cohortMuscle-invasive bladder cancerAssociated with significant morbiditySingle-institution seriesHeterogeneous group of patientsCompare oncologic outcomesINCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG
Narayan V, Boorjian S, Crispen P, Kamat A, Gomella L, Kates M, Karsh L, Master V, Richards K, Lerner S, Kim E, Inman B, Lane B, Schuckman A, Krupski T, Bardot S, Montgomery J, Busby J, Luchey A, Williams M, Agarwal P, Rehm D, Jakobsen J, Juul K, Dinney C. INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG. Urologic Oncology Seminars And Original Investigations 2025, 43: 86. DOI: 10.1016/j.urolonc.2024.12.217.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle-invasive bladder cancerCystectomy-free survivalCarcinoma in situNadofaragene firadenovecPhase 3 studyCR statusBladder cancerKaplan-MeierPathological outcomesVector-based gene therapyMedian follow-up timeBladder-sparing optionsHigh-grade recurrenceYears of follow-upRate of upstagingKaplan-Meier (KMAssociated with morbidityData cutoffImmediate cystectomyTransurethral resectionPapillary tumorsOpen-labelDefinitive treatmentEfficacy analysisB2B: Bladder Cancer Summary
Black P, Lerner S, Desai M, Konety B, Gupta S, Joshi A, Oualla K, Rajappa S, Talwar V, Prakash G, Tanguay S. B2B: Bladder Cancer Summary. Société Internationale D’Urologie Journal 2025, 6: 18. DOI: 10.3390/siuj6010018.Peer-Reviewed Original ResearchA phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaProgression-free survivalStandard of careEnfortumab vedotinOverall survivalCisplatin-ineligible metastatic urothelial carcinomaMedian progression-free survivalPhase III randomized trialStudies of eribulinMedian overall survivalPlatinum-based chemotherapyLines of therapyEndpoint of OSOne-sided alphaFGFR3 alterationsLiver metastasesSystemic therapyEligible ptsUrothelial carcinomaPrimary endpointSecondary endpointsGenitourinary cancersEribulinTreatment changesGemcitabineTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyApproach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.
Chalker C, Ong M, McKay R, Tangen C, Gulati S, Keim M, Lerner S, Dorff T, Sokolova A. Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America. Journal Of Clinical Oncology 2025, 43: 263-263. DOI: 10.1200/jco.2025.43.5_suppl.263.Peer-Reviewed Original ResearchProstate specific antigenTriplet therapyDoublet therapyGenitourinary oncologistsPatient comorbiditiesClinical trialsVolume of diseaseClinical Trials GroupOptimal clinical settingClinical trial enrollmentRandomized clinical trialsDe novoMHSPC patientsApproach to treatmentDisease volumeSystemic therapyTriple therapyYears of clinical experienceMHSPCSpecific antigenClinician specialtyPatient factorsTrial enrollmentTherapyPatientsEvaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Thompson I, Lerner S. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. Journal Of Clinical Oncology 2025, 43: 268-268. DOI: 10.1200/jco.2025.43.5_suppl.268.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerPSA responseAndrogen deprivation therapyProstate-specific antigenContinuous androgen deprivation therapyContinuous ADTOverall survivalDisease extentCox regressionHormone-sensitive prostate cancerAssociated with worse OSDe-intensification strategiesBaseline clinical featuresSubsets of patientsTreatment effectsDeprivation therapyImproved OSExtensive diseaseMinimal diseasePrognostic significanceProstate cancerOptimal therapyCox analysisLymph nodesPrognostic markerImpact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Annapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerCarcinoma in situBCG-unresponsive NMIBCBladder-sparing therapyOncological outcomesTumor stageBladder cancer mortalityCancer mortalityAssociated with worse oncologic outcomesPresence of carcinoma in situCarcinoma in situ groupImpact of tumor stageTA groupKaplan-Meier methodPapillary diseaseT1 diseaseRadical cystectomyNo significant differenceClinical stageBladder cancerSurvival differencesRetrospective natureCis groupDisease progressionMetastasis
News
News
Get In Touch
Contacts
Academic Office Number
Office Fax Number